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1. Introduction  
The popularity in natural product use we witness today arose from a growing public 
skepticism about taking “pharmaceutical chemicals” to treat illness. Such skepticism was 
supplanted by a public perception that “medications” from natural sources are safer to use 
and have similar efficacies as their pharmaceutical equivalents. The diverse assortment of 
natural products on the shelves of pharmacies, health food stores, and grocery stores attest 
to this enhanced public demand, but has compelled regulatory agencies to question the 
adequacy of the safety and efficacy data associated with the use of these products (Natural 
Health Products Directorate 2007). In the current regulatory environment, full realization of 
the wellness and therapeutic value of these natural products can only come about with more 
rigorous assessments of their safety and efficacy.  
This is particularly true of natural products that contain lignans as the principal bioactive 
component. Interest in lignans continues to grow due to an increased awareness of their 
putative health benefits. One such product, Chaparral, contains lignans extracted from 
creosote bush. Creosote bush had centuries of traditional use by aboriginal peoples of the 
Southwestern United States as an effective natural medicine and was marketed as an extract 
of the plant in capsule form based on this historical medicinal value (Clark & Reed 1992). 
While traditional creosote bush use appears to be quite safe, chronic use of Chaparral led to 
reports of toxicity (Clark & Reed 1992; Gordon et al., 1995; Batchelor et al., 1995; Grant et al., 
1998). Nordihydroguaiaretic acid (NDGA) is the major lignan in creosote bush, which is 
believed to be responsible for both the efficacious and toxic properties of Chaparral (Grice et 
al., 1968; Moore 1989; Arteaga et al., 2005; Lambert et al., 2004). Wagner and Lewis 1980 
previously reported that NDGA undergoes oxidation to “activated NDGA” (Wagner & 
Lewis 1980). Billinsky et al. 2008 suggest this “activated NDGA” is the result of an 
autoxidation process to a stable dibenzocyclooctadiene product of NDGA (Billinsky & Krol 
2008). Whether this dibenzocyclooctadiene is present in traditional creosote bush products 
or is formed in vivo is not known.  
The recent popularity of lignans from flaxseed, which are currently marketed as 
concentrated extracts of the principal plant lignan, secoisolariciresinol diglucoside (SDG), in 
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products such as Brevail™ and Beneflax™, arises from recent promising clinical trial 
evidence of their chemopreventive and therapeutic properties for a variety of chronic 
diseases (Pan et al., 2007; Hallund et al., 2008; Zhang et al., 2008). Following oral 
consumption, the glucose groups of SDG are cleaved to form the aglycone, 
secoisolariciresinol (SECO), which is further metabolized to the mammalian lignans, 
enterodiol (ED) and enterolactone (EL), by colonic bacteria (Rickard et al., 1996; Borriello et 
al., 1985a). Flaxseed also contains smaller amounts of other lignans such as mataresinol, and 
lariciresinol. The presence of anhydrosecoisolariciresinol (ASECO) was reported in flaxseed 
(Charlet et al., 2002). However, its actual presence is questioned as the acid hydrolysis 
method used to extract and quantify lignans from flaxseed can convert SECO into ASECO 
(Mazur et al., 1996). Which lignan form mediates the putative health effects is not known, 
but little evidence of toxicity exists with their use, and most clinical trial data identifies their 
relative safety. Interestingly, a comparison of the structure of NDGA from creosote bush 
with the flaxseed lignan, SDG and its aglycone form, SECO, identifies remarkable 
structurally similarity, yet with obvious differences in their safety profiles (Figure 1).  
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Fig. 1. Structures of lignans derived from Flaxseed1 and Creosote bush2. 
Why lignan in chaparral is associated with toxicity while lignans from flaxseed have limited 
reported toxicity may relate to differences in their ability to inhibit cytochrome P450 (P450) 
enzymes. Cytochrome P450 enzymes are the principal detoxification mechanisms of the 
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body and mediate the elimination of a wide variety of drugs, phytochemicals, and 
environmental toxicants. Consequently, interactions involving P450 enzymes are widely 
reported in the literature. Such P450 enzyme interactions often involve P450 inhibition, 
which may proceed either through mechanism-based, irreversible interaction with a P450 
enzyme or by a reversible competitive interaction between two substrates for the same P450. 
Both inhibition mechanisms represent common underlying mechanisms for toxicity 
associated with pharmaceutical products, phytochemicals and environmental toxicants 
(Fowler & Zhang 2008). 
Mechanism-based, irreversible inhibition of P450 usually follows from bioactivation by P450 
to a reactive metabolite that, in turn, covalently binds to the enzyme (heme or apoprotein) 
and prevents further P450 activity (Kalgutkar et al., 2007). Enzyme function is only restored 
with synthesis of new enzyme. Alternatively, the reactive metabolite may bind to other 
macromolecules (i.e. protein, nucleic acid) to inhibit their function or act as a hapten leading 
to an immune response with toxicological outcomes (Kalgutkar et al., 2007). Hence, P450-
mediated bioactivation to reactive metabolites can represent an important mechanism of 
toxicity associated with natural product use. Reversible competitive interactions at the same 
P450 can also result in toxicity when natural products are present simultaneously with other 
chemicals whose metabolic clearance is predominantly dependent upon a particular P450 
enzyme (Fowler & Zhang 2008). Competitive interactions, then, may lead to the 
accumulation of a compound and eventual toxicity. Given the potential for significant 
adverse outcomes, evaluation of P450 inhibition is commonly investigated during standard 
safety assessments for drugs, environmental contaminants, and phytochemicals.  
Our purpose was to determine whether mechanism-based, irreversible inhibition and/or 
reversible, competitive P450 inhibition might explain the differences in apparent toxicity 
between oral consumption of naturally occurring lignans from creosote bush, which have 
known toxicity, and flaxseed, which show relative safety. Additionally, such information is 
important to determine whether lignans present a significant concern with respect to their 
potential for P450-mediated interactions. As a proof-of-concept study, rat hepatic 
microsomal systems were employed to investigate the hypothesis that lignan from creosote 
bush undergoes P450-enzyme mediated bioactivation to form reactive metabolites while 
flaxseed lignans do not. Furthermore, we hypothesized that lignan from creosote bush 
inhibits P450 enzyme activity via mechanism-based and/or reversible inhibition 
mechanisms and that glutathione (GSH) can attenuate the inhibition. The use of rat also 
supports current investigations in our laboratories concerning lignan efficacy and 
pharmacokinetics in rat models of hyperlipidemia and hyperglycemia (Felmlee et al., 2009). 
Such investigations will make an invaluable contribution to our understanding of the safety 
of natural products containing lignan as the principal bioactive component. 
2. Cytochrome P450-mediated formation of reactive metabolites  
Cytochrome P450 enzyme interactions are commonly touted as a mechanism of toxicity 
(Fowler & Zhang 2008; Stresser et al., 2000). In particular, bioactivation, or the metabolic 
activation of a compound to an electrophilic reactive intermediate, which subsequently 
undergoes covalent binding to critical cellular macromolecules and interferes with their 
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function, has long-standing recognition as a biochemical mechanism of organ toxicity 
(Miller & Miller 1947; Mitchell et al., 1973; Masubuchi et al., 2007). Several examples exist of 
natural products undergoing P450-mediated bioactivation and irreversible P450 enzyme 
inhibition and hepatotoxicity (Johnson et al., 2003; Zhou et al., 2004; Surh & Lee 1995; He et 
al., 1998; Kent et al., 2002). Furthermore, natural products are known to result in significant 
interactions with coadministered therapeutic agents resulting in adverse effects or 
therapeutic failures (Dietz & Bolton 2007; Yuan et al., 2004; Kupiec & Raj 2005). With the 
growing interest in lignans for their health and wellness or therapeutic values, assessments 
of their safety are necessary to support their use.  
Structural features of the lignans suggest their potential for oxidation to quinone 
derivatives, a class of compounds known to be electrophilic reactive intermediates (Bolton et 
al., 1994; Iverson et al., 1995). Since SDG is unlikely absorbed due to the polar nature of the 
glycosidic groups, it was not investigated for their potential to undergo hepatic P450-
mediated bioactivation to a reactive intermediate. Previous studies in our laboratory 
identified NDGA’s (the major lignan of creosote bush) ability to undergo autoxidation to a 
reactive quinone species (Billinsky et al., 2007; Billinsky & Krol 2008). Billinsky et al., 2007 
had previously reported that NDGA underwent autoxidation and conversion via an ortho-
quinone reactive intermediate to three glutathione (GSH) adducts (Billinsky et al., 2007). 
Furthermore, in the absence of GSH NDGA autoxidation resulted in the formation of a 
novel dibenzocyclooctadiene (Billinsky & Krol 2008). The autoxidation of NDGA to a 
reactive intermediate in rat hepatic microsomes (Billinsky et al., 2007) did not result in the 
inactivation of P450 enzyme activity. These findings are not unexpected as the literature 
suggests ortho-quinones do not usually undergo adduct formation with cellular 
macromolecules, instead their damage is usually mediated through an increase in oxidative 
stress (Chichirau et al., 2005; O'Brien 1991; Monks et al., 1992). Although ortho-quinones may 
isomerize to para-quinone methides in vivo, a quinone derivative known to form covalent 
adducts with cellular macromolecules (Powis 1987), this process is unlikely to occur as 
NDGA is substituted at the benzylic carbon, which severely hinders the isomerization 
process (Iverson et al., 1995). 
Current studies indicate that SECO (the aglycone form of the major flaxseed lignan, SDG) 
underwent conversion to lariciresinol, both in the presence and absence of GSH, without 
formation of a stable reactive quinone intermediate. No GSH adducts were observed 
following microsomal incubations. ASECO was also examined as its structure is 
intermediate of NDGA and SECO. For ASECO, all control experiments showed no product 
formation; however, in the presence of GSH a product peak in MS-ESI(-) with a m/z 648.19 
[M-H]- was observed. This mass is consistent with the formation of an ASECO-GSH adduct, 
which is likely derived from an ASECO para-quinone methide. 
These studies, in conjunction with the growing interest in their use, compelled an 
investigation into their potential for mechanism-based inhibition and/or reversible 
inhibition of P450 isoforms. The use of in vitro microsomal systems for assessments of 
cytochrome P450 inhibition potential by drug candidates and natural products is a 
commonly employed technique to determine the likelihood for pharmacokinetic interactions 
resulting from P450 enzyme inhibition (Stresser et al., 2000).  
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3. Mechanism-based inhibition of cytochrome P450 enzymes 
We examined the ability of creosote bush and flaxseed lignans to inhibit the activity of 
CYP3A, CYP2C and CYP1A2 enzymes as these isoforms are principally involved in the 
metabolism of drugs and other natural products on the market today. To determine 
whether lignans result in mechanism-based inhibition of P450 enzymes initial 
experiments examined the extent of inhibition as a function of pre-incubation time and 
lignan concentration.  
SDG did not cause mechanism-based inhibition of any P450 isoform at any concentration 
tested. The data also suggests that SDG does not cause reversible inhibition of P450 
isoforms, as metabolite formation remained the same at pre-incubation time 0 at all SDG 
concentrations tested. This result was not unexpected given the physicochemical 
characteristics of SDG. Hydrophilic molecules tend not to be substrates for P450 enzymes 
and are primarily eliminated from the body via renal elimination mechanisms. 
Furthermore, studies have failed to detect systemic levels of SDG (Kuijsten et al., 2005b), 
suggesting that it is not absorbed from the gastrointestinal tract or undergoes extensive 
first pass metabolism. Studies further suggest that this first-pass metabolism occurs at the 
gastrointestinal level, where the glucosidic groups of SDG are cleaved to produce the 
aglycone, SECO (Thompson et al., 1991; Borriello et al., 1985c). SECO is likely the flaxseed 
lignan form available for absorption following the oral consumption of flaxseed products 
(Nesbitt et al., 1999; Axelson et al., 1982d).  
SECO did not cause significant inhibition of CYP1A2. SECO inhibited CYP3A in a 
concentration-dependent but not time-dependent manner suggesting that SECO is a 
reversible inhibitor of the three isoforms. Reversible inhibition is consistent with the lack of 
GSH adduct formation following microsomal incubation of SECO in the presence of GSH. 
However, at 2000 μM SECO inhibited 6ǃ-, 16ǂ- and 2ǂ-hydroxytestosterone formation by 
only 36.2 ± 7.26%, 65.7 ± 8.36% and 64.4 ± 6.36%, respectively.  
ASECO caused limited inhibition of CYP1A2, 2B, and 2C11, with moderate inhibition of 
CYP3A at the highest concentration (100 µM) resulting in 49.2 ± 1.8% inhibition after 20 
minutes preincubation. As with SDG and SECO, ASECO showed concentration-dependent 
but not time-dependant inhibition which suggests P450 inhibition by reversible 
mechanisms. These results are interesting, as in the presence of GSH, we observed an 
ASECO adduct that was consistent with para-quinone methide formation (Bolton et al., 1994; 
Awad et al., 2002). Despite this observation, mechanism-based inhibition of P450 activity 
was not identified in our studies.  
Enterodiol (ED) failed to inhibit P450 activity and rather caused activation of CYP1A2, 3A, 
2B and 2C11 activity particularly at shorter preincubation times (Figure 2). Although an 
apparent inhibition of CYP3A activity was observed after a 20 min pre-incubation (Figure 
2b), control samples without ED showed a large %CV of 91.8% relative to the samples pre-
incubated with ED for 20 min.  
EL caused concentration-dependent, but not time-dependent, inhibition of CYP1A2 and 
only at high concentrations with 500 µM EL inhibiting CYP1A2 to 14.3 ± 23% that of control 
(data not shown). EL also caused concentration-dependent inhibition of CYP3A. 
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Interestingly, EL caused activation of 16ǂ-hydroxytestosterone (16ǂ-OH) formation, a 
metabolite pathway shared by CYP2B and CYP2C11. Given the ability of EL to inhibit 2ǂ-
OH formation, a pathway largely catalyzed by CYP2C11, increased 16ǂ-OH formation may 
be due to activation of CYP2B activity by EL.  
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Fig. 2. Cytochrome P450 enzyme activity (as percent of control) as a function of Enterodiol 
concentration and pre-incubation time. a) CYP1A2, b) CYP3A, c) CYP2B/2C11 and  
d) CYP2C11. Enterodiol (closed diamond = 0 µM; closed square = 50 µM; closed  
triangle = 100 µM; symbol ‘x’ = 250 µM; open circle = 500 µM) was pre-incubated in pooled 
male rat hepatic microsomes (n=4) for different time periods. At the end of each  
pre-incubation period, testosterone (50 µM) and methoxyresorufin (0.5 µM) was added and 
metabolite formation was determined after a 15 min and 8 min reaction time, respectively. 
Each point is the mean of 3 replicates ± percent coefficient of variation. 
NDGA generally caused concentration-dependent but not time-dependent inhibition of all 
CYP isoforms (data not shown). We anticipated that NDGA could be an irreversible 
inhibitor given its ability to form a reactive ortho-quinone intermediate. Since this is an 
autoxidation process and not a P450 catalyzed process, it appears that the ortho-quinone 
does not inhibit P450 in vitro (Billinsky et al., 2007; Billinsky & Krol 2008). Generally, marked 
inhibition was not observed until NDGA concentrations reached 100 μM or higher. At a pre-
incubation time of 20 minutes and a concentration of 200 µM, NDGA inhibited CYP1A2, 
2B/2C11 and 2C11 to 3.55 ± 12.0%, 21.2 ± 8.81% and 21.2 ± 9.37% of control, respectively. 
NDGA caused complete inhibition of formation of 6ǃ-OH via CYP3A at pre-incubation time 
of 20 minutes and a concentration of 200 µM.  
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The NDGA dibenzocyclooctadiene did not cause significant inhibition of CYP2B/2C11 and 
did not cause time-dependant inhibition of any of the tested isoforms (data not shown). The 
NDGA dibenzocyclooctadiene significantly inhibited CYP3A and CYP1A2 to 42.9 ± 3.6%, 
and 13.9 ± 4.3% of control, respectively, at 100 µM. 
Our studies provided no evidence of mechanism-based inhibition of the P450 enzymes by 
either the lignans of creosote bush or flaxseed.  
4. Reversible inhibition of cytochrome P450 enzymes 
To determine whether lignans inhibit specific P450 enzymes through reversible 
mechanisms, we monitored the metabolite formation of P450-probe substrates by rat hepatic 
microsomes in the presence of different concentrations of lignan and probe substrates. Since 
time- and concentration-dependent experiments indicated that SDG and ED were neither 
reversible nor irreversible inhibitors of P450 enzyme activity, we excluded SDG and ED 
from our evaluations for reversible inhibition. We estimated the % inhibition at each lignan 
concentration and when possible estimated the IC50 values to provide a measure of potency 
of the inhibition. Lineweaver-Burke plots were constructed to determine the mechanism of 
inhibition. HPLC results from lignan incubations indicated substrate depletion at a 
testosterone concentration of 25 µM, representing ½ KM for the substrate. Consequently, this 
concentration was not included in any of the graphical representations and analysis. 
Reversible inhibition of P450 enzyme activity by the flaxseed lignans tended to show more 
specificity than the creosote bush lignans. Although our studies provide evidence of 
reversible inhibition of rat P450 enzyme activity by the lignans of creosote bush and 
flaxseed, such inhibition required rather high lignan concentrations. 
Our data suggest SECO is a more specific inhibitor of P450 enzymes and causes a marked 
reduction in CYP3A activity only at high SECO concentrations. Such concentrations are 
substantially greater than the levels anticipated under physiological conditions (25-100 μM) 
(Hu et al., 2007). Our data also show that SECO activates CYP2B activity at lower probe 
substrate concentrations.  
SECO caused a concentration-dependent decrease in 6ǃ-OH formation, which is mediated 
by CYP3A (Figure 3a). A plot of 6ǃ-OH formation (at KM) as a function of the logarithmic 
concentration of SECO yielded an IC50 value of 373 µM (95% CI 266-523). A Lineweaver-
Burke plot showed a pattern almost consistent with that of competitive inhibition, but the 
lines intersected in the upper right hand quadrant near the y-axis (not shown). This suggests 
SECO inhibits CYP3A activity consistent with atypical Michaelis-Menten kinetics (Folk et 
al., 1962; Atkins 2005).  
The formation of 16ǂ-OH testosterone, representing CYP2B/2C11 activity, was largely 
unaffected by SECO at testosterone concentrations of 100 and 250 µM (Figure 3b). At 50 µM 
testosterone, SECO concentrations ≥50 µM increased the formation of 16ǂ-OH testosterone. 
Since CYP2C11 activity was generally unaffected by SECO (Figure 3c), SECO-mediated 
activation of CYP2B likely explains the increased formation of 16ǂ-OH testosterone. The 
percent of control activity of the various CYP isoforms tested at KM, 2×KM and VMax 
testosterone is summarized in Table 1.  
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Fig. 3. Secoisolariciresinol (SECO) concentration dependent inhibition of a) CYP3A,  
b) CYP2B/2C11 and c) CYP2C11 using testosterone (solid bar = 50 µM; open bar = 100 µM; 
stipled bar = 250 µM) as the probe substrate in incubation reactions (15 min) with pooled 
(n=4) male, rat liver microsomes. Each point represents the mean of 3 replicates ± percent 
coefficient of variation. 
 
 6ǃ-OHT (CYP3A) 16ǂ-OHT 
(CYP2B/2C11) 
2ǂ-OHT 
(CYP2C11) 
 Percent of Control 
Activity 
(mean ± % CV) 
Percent of Control 
Activity 
(mean ± % CV) 
Percent of Control 
Activity 
(mean ± % CV) 
Testosterone/ 
Methoxyresorufin 
SECO 
50 μM 
SECO 
1600 
μM 
SECO 
50 μM 
SECO 
1600 
μM 
SECO 
50 μM 
SECO 
1600 
μM 
KM 90.7 ± 
5.0 
29.0 ± 
11 
117.5 ± 
5.1 
172 ± 
8.1 
106.1 ± 
1.7 
86.0 ± 
7.6 
2KM 86.4 ± 
1.1 
31.8 ± 
11 
91.0 ± 
0.5 
87.4 ± 
5.2 
97.3 ± 
0.5 
75.0 ± 
4.0 
VMax 91.9 ± 
3.6 
42.4 ± 
3.1 
98.4 ± 
2.8 
80.9 ± 
5.2 
97.1 ± 
2.3 
71.9 ± 
3.3 
Table 1. The percent of control activity (mean ± % CV) for the formation of 6ǃ-, 16ǂ- and  
2ǂ-hydroxytestosterone (OHT) in pooled (n=4) rat liver microsomes by 50 and 1600 μM 
Secosiolariciresinol (SECO) at the KM, 2×KM and ~VMax of testosterone. 
We further examined the ability of an additional flaxseed lignan, ASECO, to inhibit P450 
enzyme activity. Whether ASECO is present in flaxseed remains controversial as the 
identification of ASECO in flaxseed may be an artifact of the analytical techniques employed 
by Charlet et al. (Charlet et al., 2002). Our lab has produced ASECO by acid hydrolysis of 
SECO using the same methods as Charlet et al., 2002 (Charlet et al., 2002). Furthermore, 
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ASECO could be formed during the isolation process for lignan enriched flaxseed products 
such as Beneflax™, and with oral consumption of flaxseed lignan products small amounts of 
ASECO could form within the acidic environment of the stomach. Such factors warranted an 
examination of ASECO’s ability to inhibit P450 enzyme activity.  
Pre-incubation time- and concentration- dependant experiments showed that ASECO was 
not an inhibitor of CYP2B/2C11. Due to overlapping and unresolvable HPLC peaks, the 
inhibition of CYP2C11, measured by 2ǂ-OH testosterone formation could not be assessed.  
ASECO maximally inhibited CYP1A2 when methoxyresorufin concentration was at the KM 
of the enzyme, with the greatest extent of inhibition occurring at 100 µM ASECO (70.8 ± 
3.9% of control) (Figure 4a). Further increases in the extent of inhibition at higher ASECO 
concentrations was not observed, but this may be due to an inability to completely solubilize 
ASECO. Therefore, data for 150 and 200µM are not shown. ASECO generally caused a 
concentration-dependent inhibition of CYP3A at all testosterone concentrations, although 
the pattern of inhibition became inconsistent at ASECO concentrations beyond 100 µM, 
which is likely due to solubility issues (Figure 4b). The percent of control activity of the 
formation of resorufin and 6ǃ-OH tested at KM, 2×KM and VMax of methoxyresorufin and 
testosterone is summarized in Table 2. A plot of the 6ǃ-OH formation (at KM) as a function 
of the logarithmic concentration of ASECO yielded an IC50 value of 36.4 µM (95% CI 21.9-
60.3). The IC50 value for CYP1A2 inhibition was greater than 200 µM. A Lineweaver-Burke 
plot gave parallel lines, a pattern consistent with uncompetitive inhibition (not shown). 
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Fig. 4. Anhydrosecoisolariciresinol (ASECO) concentration dependent inhibition of  
a) CYP1A2 and b) CYP3A using methoxyresorufin (solid bar = 0.5 µM; open bar = 1 µM; 
stipled bar = 2.5 µM) and testosterone (solid bar = 50 µM; open bar = 100 µM;  
stipled bar = 250 µM) as the probe substrates, respectively, in incubation reactions  
(8 min and 15 min, respectively) with pooled (n=4) male, rat liver microsomes. Each point 
represents the mean of 3 replicates ± percent coefficient of variation. 
SDG (and SECO) is often referred to as the precursor for the enterolignans, ED and EL 
(Thompson et al., 1991; Borriello et al., 1985a; Kuijsten et al., 2005; Axelson et al., 1982c; 
Bambagiotti-Alberti et al., 1994). Much of the putative health benefits of flaxseed lignans are 
ascribed to the enterolignan forms, although definitive data for such assertions is lacking. 
Following oral consumption, SDG is converted to SECO, which further undergoes 
metabolism to ED and then to EL by colonic bacterial activity (Axelson et al., 1982b). The 
literature reports significant systemic and urinary levels of EL and its conjugated forms 
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(Jacobs et al., 1999; Axelson et al., 1982a) and much lower levels of ED suggesting that EL 
and ED are absorbed following their conversion within the gastrointestinal tract. This 
warranted an investigation of their potential to inhibit P450 enzyme activity.  
 
 Resorufin (CYP1A2) 6ǃ-OHT (CYP3A) 
 Percent of Control 
Activity 
(mean ± % CV) 
Percent of Control 
Activity 
(mean ± % CV) 
Testosterone/ 
Methoxyresorufin 
ASECO 
25 μM 
ASECO 
100 μM 
ASECO 
25 μM 
ASECO 
100 μM 
KM 89.6 ± 19.5 70.8 ± 3.9 74.0 ±3.5 40.9 ± 6.5 
2KM 87.5 ± 14.1 86.4 ± 14.0 55.5 ± 7.8 15.6 ± 10.2 
VMax 102.6 ± 3.8 94.7 ± 12.5 59.7 ± 12.2 65.2 ± 28.7 
Table 2. The percent of control activity (mean ± % CV) for the formation of  
6ǃ-hydroxytestosterone (OHT) and resorufin in pooled (n=4) rat liver microsomes by 25 and 
100 μM Anhydrosecosiolariciresinol (ASECO) at the KM, 2×KM and ~VMax of testosterone or 
methoxyresorufin. 
Enterodiol caused CYP2B/2C11 activation in time- and concentration-dependent 
experiments and thus was not examined for reversible inhibition of these enzymes. EL 
maximally inhibited CYP1A2 when methoxyresorufin concentration was at the KM of the 
enzyme (Figure 5a). EL also caused a concentration-dependent decrease in resorufin 
formation at 2× KM and VMax methoxyresorufin concentrations (Figure 5a). At the KM of 
testosterone, EL did not inhibit CYP3A activity and at 500 µM EL, a 3-fold increase in 
metabolite formation was observed (Figure 5b). However, at 2×KM and VMax testosterone 
concentrations, EL generally caused a concentration-dependent decrease in CYP3A-
mediated 6ǃ-OH formation (Figure 5b). For CYP2C11, at the KM of testosterone, EL 
generally increased the rate of 2ǂ-OH formation at all EL concentrations. However, EL 
caused pronounced inhibition at 2×KM and VMax testosterone concentrations for the enzyme 
(Figure 5c). Plots of metabolite formation (at KM) as a function of the logarithmic 
concentration of EL yielded IC50 values of 441 µM (95% CI 115-1695), 72.9 µM (95% CI 54.0-
98.2) (determined at the VMax due to activation at KM) and 104 µM (95% CI 85.7-127) 
(determined at the VMax due to activation at KM) for CYP1A2, CYP3A and CYP2C11, 
respectively. The percent of control activity of the various CYP isoforms tested at KM, 2× KM 
and VMax of methoxyresorufin or testosterone is summarized in Table 3.  
Lineweaver-Burke plots were difficult to interpret for EL inhibition of CYP1A2, although the 
pattern was somewhat consistent with that of competitive inhibition, with the lines 
intersecting in the upper right hand quadrant (not shown). However, the pattern of the plots 
for CYP2C11 and CYP3A were consistent with noncompetitive inhibition by EL.  
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Fig. 5. Enterolactone concentration dependent inhibition of a) CYP1A2, b) CYP3A and  
c) CYP2C11 using methoxyresorufin (solid bar = 0.5 µM; open bar = 1 µM; stipled bar = 2.5 
µM) and testosterone (solid bar = 50 µM; open bar = 100 µM; stipled bar = 250 µM) as the 
probe substrates, respectively, in incubation reactions (8 min and 15 min, respectively) with 
pooled (n=4) male, rat liver microsomes. Each point represents the mean of 3 replicates ± 
percent coefficient of variation. 
 
 
Resorufin 
(CYP1A2) 
6ǃ-OHT 
(CYP3A) 
16ǂ-OHT 
(CYP2B/2C11) 
2ǂ-OHT 
(CYP2C11) 
 
Percent of 
Control Activity 
(mean ± % CV) 
Percent of 
Control 
Activity 
(mean ± % CV) 
Percent of 
Control Activity 
(mean ± % CV) 
Percent of 
Control Activity 
(mean ± % CV) 
Testosterone/ 
Methoxy-
resorufin 
EL 
100 
μM 
EL 
500 
μM 
EL 
100 
μM 
EL 
500 
μM 
EL 
100 
μM 
EL 
500  
μM 
EL 
100 
μM 
EL 
500  
μM 
KM 
74.2 ± 
13.8 
24.7 ± 
23.7 
95.1 ± 
26.8 
309.9 
± 26.0 
262.7 
± 17.1 
302.5 ± 
11.4 
176.2 
± 13.2 
120.2 ± 
48.1 
2KM 
97.4 ± 
12.2 
42.6 
±1.0 
45.5 ± 
4.2 
55.0 ± 
0.7 
86.9 ± 
1.8 
61.9 ± 
2.1 
51.0 ± 
2.9 
42.4 ± 
1.9 
VMax 
96.7 ± 
1.1 
64.7 ± 
1.6 
52.0 ± 
6.4 
50.2 ± 
2.3 
75.4 ± 
5.4 
60.1 ± 
2.7 
53.9 ± 
5.5 
43.0 ± 
1.7 
Table 3. The percent of control activity (mean ± % CV) for the formation of resorufin, and 
6ǃ-, 16ǂ- and 2ǂ-hydroxytestosterone (OHT) in pooled (n=4) rat liver microsomes by 100 
and 500 μM Enterolactone (EL) at the KM, 2×KM and ~VMax of methoxyresorufin or 
testosterone. 
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In general, NDGA caused a concentration-dependent decrease in CYP1A2, CYP3A, CYP2B 
and CYP2C11 activity (Figure 6). For CYP1A2, NDGA caused more prominent inhibition at 
the KM of methoxyresorufin (Figure 6a), but for the CYP3A, CYP2B/2C11, and CYP2C11, 
NDGA caused most pronounced inhibition of testosterone metabolite formation at the VMax 
for testosterone (Figure 6b, 6c, 6d). Furthermore, at the KM of testosterone, NDGA increased 
the 16ǂ- and 2ǂ-hydroxylation of testosterone, index pathways for CYP2B/2C11 and 
CYP2C11, respectively. Activation of metabolism was more pronounced for 16ǂ-OH 
formation. The IC50 values were calculated at the KM of the substrate for CYP1A2 and 
CYP3A and at VMax for testosterone for CYP2B/2C11 and CYP2C11, as activation was 
observed at the KM for CYP2B/2C11 and CYP2C11. Plots of metabolite formation as a 
function of the logarithmic concentration of NDGA yielded IC50 values of 63.5 µM (95% CI 
11.8-341), 97.3 µM (95% CI 49.6-191), 68.7 µM (95% CI 46.4-102) and 96.6 µM (95% CI 55.3-
169) for CYP1A2, CYP3A, CYP2B/2C11 and CYP2C11, respectively. The percent of control 
activity of the various CYP isoforms tested at KM, 2×KM and VMax of methoxyresorufin or 
testosterone is summarized in Table 4.  
 
 
Resorufin 
(CYP1A2) 
6ǃ-OHT 
(CYP3A) 
16ǂ-OHT 
(CYP2B/2C11) 
2ǂ-OHT 
(CYP2C11) 
 
Percent of 
Control Activity
(mean ± % CV) 
Percent of 
Control Activity
(mean ± % CV) 
Percent of 
Control Activity
(mean ± % CV) 
Percent of 
Control Activity 
(mean ± % CV) 
Testosterone/ 
Methoxy-
resorufin 
NDGA
25 μM 
NDGA
200 μM
NDGA
25 μM 
NDGA
200 μM
NDGA
25 μM 
NDGA
200 μM
NDGA 
25 μM 
NDGA 
200 μM 
KM 
84.1 ± 
16.2 
6.7 ± 
13.5 
81.8 ± 
6.4 
17.6 ± 
11.7 
158.3 ± 
6.2 
123.2 ± 
8.8 
118.0 ± 
3.9 
57.3 ± 
8.6 
2KM 
100.6 ± 
1.7 
17.9 ± 
4.2 
66.6 ± 
1.8 
12.4 ± 
30.7 
88.7 ± 
4.5 
42.2 ± 
26.0 
93.0 ± 
2.9 
37.5 ± 
26.1 
VMax 
109.1 ± 
1.1 
40.2 ± 
7.9 
63.6 ± 
3.9 
11.1 ± 
3.5 
79.8 ± 
3.4 
27.6 ± 
0.3 
88.7 ± 
3.8 
29.7 ± 
0.1 
Table 4. The percent of control activity (mean ± % CV) for the formation of resorufin, and 
6ǃ-, 16ǂ- and 2ǂ-hydroxytestosterone (OHT) in pooled (n=4) rat liver microsomes by 25 and 
200 μM Nordihydroguaiaretic acid (NDGA) at the KM, 2×KM and ~VMax of methoxyresorufin 
or testosterone. 
Lineweaver-Burke plots for NDGA inhibition of CYP1A2 showed a pattern consistent 
with competitive inhibition, but with the lines intersecting in the upper right hand 
quadrant near the y-axis (not shown). For CYP3A the pattern was consistent with 
noncompetitive inhibition. For the CYP2B/2C11 and CYP2C11 pathways, the Lineweaver-
Burke plots were more difficult to interpret. At higher NDGA concentrations, parallel 
lines suggested uncompetitive inhibition. However, activation of these pathways at the 
KM of testosterone (Figure 6c and 6d) likely affected the overall pattern observed in these 
plots (not shown). 
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Fig. 6. Nordihydroguaiaretic acid (NDGA) concentration dependent inhibition of a) CYP1A2, 
b) CYP3A c) CYP2B/2C11, and d) CYP2C11 using methoxyresorufin (solid bar = 0.5 µM;  
open bar = 1 µM; stipled bar = 2.5 µM) and testosterone (solid bar = 50 µM; open bar = 100 µM; 
stipled bar = 250 µM) as the probe substrates, respectively, in incubation reactions (8 min 
and 15 min, respectively) with pooled (n=4) male, rat liver microsomes. Each point 
represents the mean of 3 replicates ± percent coefficient of variation. 
Although previous studies showed that in the presence of GSH NDGA is oxidized to 
NDGA-GSH adducts and prevents the formation of NDGA dibenzocyclooctadiene 
(Billinsky & Krol 2008a), inhibition of P450 activity was still observed. For NDGA 
dibenzocyclooctadiene, the activity of CYP2C11, as monitored by 2ǂ-OH testosterone 
formation, could not be assessed, as the dibenzocyclooctadiene eluted at the same retention 
time as 2ǂ-OH testosterone during the HPLC run. There was sufficient peak overlap which 
could not be separated so we could not accurately achieve reliable data. For CYP1A2, the 
dibenzocyclooctadiene caused more prominent inhibition at the KM of methoxyresorufin 
(Figure 7a), but for CYP3A and CYP2B/2C11 slightly greater inhibition of testosterone 
metabolite formation at the testosterone VMax was observed (Figure 7b, 7c). At the VMax of 
testosterone, dibenzocyclooctadiene concentrations of 50 to 150 µM increased the formation 
of resorufin, an index pathway for CYP1A2 (Figure 7a). Dibenzocyclooctadiene did not 
cause significant inhibition of CYP2B/2C11 as evidenced by no substantial decrease in 16ǂ-
OH formation (Figure 7c). Plots of metabolite formation as a function of the logarithmic 
concentration of NDGA dibenzocyclooctadiene yielded an IC50 value of 36.8 µM (95% CI 
25.3-53.6) for CYP3A. For CYP1A2, the data did not yield an interpretable value due to 
extensive variation in the data. The percent of control activity of the various CYP isoforms 
tested at KM, 2×KM and VMax of methoxyresorufin or testosterone is summarized in Table 5.  
Lineweaver-Burke plots for dibenzocyclooctadiene inhibition of CYP1A2 showed a pattern 
consistent with competitive inhibition, but with the lines intersecting in the upper right 
hand quadrant near the y-axis and for CYP3A the pattern was consistent with 
noncompetitive inhibition (not shown). 
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Fig. 7. Dibenzocyclooctadiene (cyclolignan) concentration dependent inhibition of  
a) CYP1A2, b) CYP3A, and c) CYP2B/2C11 using methoxyresorufin (solid bar = 0.5 µM; 
open bar = 1 µM; stipled bar = 2.5 µM) and testosterone (solid bar = 50 µM; open bar = 100 µM; 
stipled bar = 250 µM) as the probe substrates, respectively, in incubation reactions (8 min 
and 15 min, respectively) with pooled (n=4) male, rat liver microsomes. Each point 
represents the mean of 3 replicates ± percent coefficient of variation. 
 
 
Resorufin 
(CYP1A2) 
6ǃ-OHT (CYP3A) 16ǂ-OHT 
(CYP2B/2C11) 
 
Percent of Control 
Activity 
(mean ± % CV) 
Percent of Control 
Activity 
(mean ± % CV) 
Percent of Control 
Activity 
(mean ± % CV) 
Testosterone/ 
Methoxyresorufin 
DIB 
50 μM 
DIB 
200 μM 
DIB 
12.5 μM
DIB 
100 μM 
DIB 
12.5 μM 
DIB 
100 μM 
KM 90.3 ± 2.5
45.3 ± 
1.0 
71.5 ± 
7.4 
26.9 ± 3.5 96.8 ± 7.0 82.0 ± 2.5 
2KM 
107.4 ± 
12.4 
68.6 ± 
12.1 
74.0 ± 
3.5 
21.8 ± 
10.0 
91.3 ± 4.1 60.4 ± 8.2 
VMax 
153.8 ± 
12.7 
103.4 ± 
4.8 
70.0 ± 
2.2 
26.4 ± 8.0 85.4 ± 2.9 59.6 ± 7.0 
Table 5. The percent of control activity (mean ± % CV) for the formation of resorufin, and 
6ǃ-, 16ǂ- and 2ǂ-hydroxytestosterone (OHT) in pooled (n=4) rat liver microsomes by 12.5, 
50, 100 and 200 μM Dibenzocyclooctadiene (DIB) at the KM, 2×KM and ~VMax of 
methoxyresorufin or testosterone. 
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5. Inhibition of CYP1A2 by nordihydroguaiaretic acid in the presence of 
glutathione 
The effect of adding GSH to microsomal incubations before the addition of NDGA was 
studied to determine whether GSH could attenuate inhibition at various time and inhibitor 
concentrations. GSH had little impact on NDGA inhibition of CYP1A2 activity (data not 
shown). The calculated IC50 for NDGA in the presence and absence of GSH was 63.5 µM 
(95% CI 11.8-341) and 80.1 µM (95% CI 22.6-284), respectively, for CYP1A2. These 
observations suggest that GSH in vitro does not protect against reversible P450 inhibition by 
the creosote bush lignan, NDGA.  
Interestingly, at lower probe substrate concentrations (50 µM) for NDGA, GSH attenuated 
inhibition, and appeared to cause activation of CYP1A2 (not shown), while 
dibenzocyclooctadiene increased the metabolite formation of the index pathway for 
CYP2B/2C11. Although P450 enzyme activation has been observed for other compounds 
(Stresser et al., 2000c; Lasker et al., 1984), the relevance of this phenomenon on in vivo 
metabolism is not known (Stresser et al., 2000b; Houston & Kenworthy 2000).  
6. Summary of inhibition of rat CYP3A, CYP2B, CYP2C11 and CYP1A2 by 
lignans 
Lineweaver-Burke plots of the inhibition data suggest that lignans largely caused reversible 
inhibition via a combination of competitive, noncompetitive, and uncompetitive 
mechanisms. The lignans EL, NDGA and its dibenzocyclooctadiene autoxidation product, 
inhibited a combination of CYP3A, CYP2B/2C11 and CYP1A2 activity suggesting that these 
lignans act as general reversible inhibitors of P450 activity. Interestingly, EL also activated 
the CYP2B/2C11 index pathway, the relevance of which is not known.  
The ability of lignans to activate P450 enzyme activity in the presence of low probe substrate 
concentrations for the P450 index pathways may account for the mixed type inhibition we 
observed (Stresser et al., 2000). Nonetheless, our in vitro results suggest that potential for 
pharmacokinetic interactions via inhibition of P450-mediated elimination by flaxseed 
lignans is extremely limited. Concentration at the P450 active site is a principal determinant 
of the potential for clinically relevant interactions (Bjornsson et al., 2003). Systemic levels 
reported in the literature suggest that lignan concentrations achieved at the P450 active site 
would be insufficient to cause significant inhibition. Even following oral consumption, 
when portal vein concentrations and hence, hepatic concentrations, of lignans are expected 
to be much greater than systemic levels, the competing phase II reactions (i.e. 
glucuronidation, sulfation) (Axelson & Setchell 1980; Dean et al., 2004) would diminish the 
availability of lignans at the P450 enzyme active sites. The clinical use of lignans should not 
be associated with adverse outcomes resulting from inhibition of P450-mediated 
metabolism. 
Table 6 summarizes the estimated IC50 values for lignan-mediated reversible inhibition 
different P450 isoforms. For lignans that failed to inhibit specific P450 isoforms the value 
reported represents the solubility limit for the respective lignan. Table 7 summarizes the 
type of reversible inhibition mechanism exhibited by each lignan for a particular P450 
isoform.  
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 CYP1A2 CYP3A 
CYP2B/ 
CYP2C11 
CYP2C11 
Secoisolariciresinol NDa 
373 
(266-523) 
> 1600 > 1600 
Anhydrosecoisolariciresinol > 200 
36.4 
(21.9-60.3) 
> 200 NDb 
Enterolactone 
441 
(115-1695) 
72.9c 
(54.0-98.2) 
> 500 
 
104c 
(85.7-127) 
Nordihydroguaiaretic 
acid 
63.5 
(11.8-341) 
97.3 
(49.6-191) 
68.7c 
(46.4-102) 
96.6c 
(55.3-169) 
Dibenzocyclooctadiene NDa 
36.8 
(25.3-53.6) 
NDa NDb 
ND = not determined  
aNo inhibition was observed at any lignan concentration 
bCould not assess due to overlapping peak on high performance liquid chromatography 
cIC50 assessed at VMax 
Table 6. Summary of estimated lignan IC50 values (µM) (with 95% confidence intervals 
displayed in brackets) for CYP1A2, CYP 3A, CYP2B/2C11 and CYP2C11. IC50 values were 
determined at probe substrate KM, except where noted.  
 
 CYP1A2 CYP3A 
CYP2B/ 
CYP2C11 
CYP2C11 
Secoisolariciresinol NO Competitive NOa NO 
Anhydro-
secoisolariciresinol 
Uncompetitive Uncompetitive NO NO 
Enterolactone Competitive Noncompetitivea NOa Noncompetitivea 
Nordihydroguaiaretic 
acid 
Competitive Noncompetitive Uncompetitivea Uncompetitivea 
Dibenzocyclooctadiene Competitive Noncompetitive NO Could not assess 
NO = No inhibition was observed 
aActivation of P450 activity was observed. 
Table 7. Summary of the type of P450 enzyme inhibition caused by lignans of creosote bush 
and flaxseed. 
7. Conclusions 
In conclusion, our data does not support the hypothesis that the differential toxicity between 
lignans of creosote bush and flaxseed may be due to differences in their capacity to undergo 
P450-mediated bioactivation to electrophilic reactive intermediates or reversible P450 
enzyme inhibition. NDGA’s autoxidation to a reactive quinone intermediate warrants 
further investigation as a possible mechanism associated with its known toxicity. 
Nonetheless, our in vitro data suggests the potential for inhibition of P450-mediated 
elimination of compounds by the lignans of creosote bush and flaxseed is limited. Their use 
for promotion of health and wellness or for therapeutic reasons should not be associated 
with adverse outcomes resulting from inhibition of P450-mediated metabolism. For the 
flaxseed lignans, our in vitro metabolism data is supported by the emerging clinical data on 
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flaxseed lignan administration where no adverse effects have been reported as of yet. Such 
promising clinical trial data associated with the flaxseed lignans warrants further 
evaluations of their safety and efficacy, which remains a focus in our laboratory. 
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